Gene study aims to personalize breast cancer drug for 600 patients
NCT ID NCT06062810
First seen Mar 17, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study looks at how small genetic differences (SNPs) in certain genes affect how well the drug raloxifene works and its side effects in people with a type of early breast cancer called LCIS. Researchers will analyze DNA from 600 participants to find gene patterns linked to better treatment outcomes or higher risk of side effects. The goal is to make treatment more personalized and safer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medicine Invention Design, Inc. - IORG0007849 - NPI 1023387701
Rockville, Maryland, 20853, United States
Conditions
Explore the condition pages connected to this study.